EPINEPHrine (EENT)
Drug class: Antineoplastic Agents
Usage of EPINEPHrine (EENT)
Open-Angle Glaucoma
Reduction of elevated IOP in patients with open-angle glaucoma. Generally used adjunctively with topical miotics, topical β-adrenergic blocking agents, osmotic agents, and/or systemically administered carbonic anhydrase inhibitors; may have an additive effect on IOP lowering. Epinephrine in conjunction with miotics may reduce miosis and ciliary spasm that often occur when miotics are used alone.
Patient response to epinephrine is highly variable; some patients are unresponsive. Repeated tonometric readings are advisable during the course of treatment, especially in geriatric patients.
Diagnosis of open-angle glaucoma by careful gonioscopic and slit lamp studies; use in patients with angle-closure glaucoma or those who may be predisposed to angle closure is contraindicated.
Mydriasis for Surgery
Although less effective than other mydriatics in normal eyes, epinephrine produces effective mydriasis when the permeability of the eye is increased by trauma (e.g., during surgery).
Induction of rapid mydriasis during surgery (e.g., cataract extraction) via topical application to the conjunctiva or injection into the anterior chamber of the eye.
Mydriasis for SyneChiae
Prolonged topical contact (e.g., via a saturated cotton wick) with the eye to induce sufficient mydriasis to break posterior synechiae† [off-label].
Administered suBConjunctivally concomitantly with atropine and cocaine to produce mydriasis and thereby break posterior synechiae† [off-label] unresponsive to topical therapy.
Mydriasis for Ophthalmoscopy
Although generally contraindicated in patients with angle-closure glaucoma, epinephrine may be used to produce mydriasis for ophthalmoscopy† [off-label] in patients predisposed to angle closure. Give a carbonic anhydrase inhibitor and an osmotic agent (e.g., glycerin) orally prior to the examination. However, even these measures may not prevent attacks of acute angle-closure glaucoma unresponsive to treatment; surgery may be required.
Superficial Bleeding
Used locally as a hemostatic agent to control superficial bleeding from arterioles and capillaries in the skin and mucous membranes of the eye, nose, mouth, throat or larynx, mainly during surgery. Ineffective for bleeding from larger vessels.
Especially useful to prevent oozing from small vessels that obscures surgical details during ophthalmic surgery.
Especially useful as a hemostatic agent in dental surgery.
Adjunct to Local Anesthesia
Added to solutions of some local anesthetics to decrease the rate of their vascular absorption (to localize and prolong the duration of anesthesia). Risk of systemic toxicity caused by the local anesthetic also is decreased, and bleeding in the operative field may be reduced.
Adjunct to Other Local Drugs
Enhancement of intraocular penetration of subconjunctivally injected drugs† [off-label]. Local vasoconstriction enhances local effect secondary to decreased drug loss from the subconjunctival depot into systemic circulation, with resultant increased intraocular penetration.
Vasoconstriction to decrease conjunctival hyperemia and thus enhance location of extraocular muscles prior to botulinum toxin injection into these muscles† [off-label]. Also reduces the risk of subconjunctival hemorrhage secondary to conjunctival vessel damage.
Conjunctivitis
Decongestion when applied topically to the conjunctiva for conjunctivitis secondary to nonspecific chronic irritation or allergy. Decongestion usually persists less than 1 hour and may be followed by reactive hyperemia. Longer-acting decongestants are preferred.
Nasal Congestion
Decongestion for allergic or nonallergic rhinitis or acute sinusitis when applied topically to the nasal mucosa. Duration of action is short and rebound congestion frequently occurs. Longer-acting decongestants are preferred.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use EPINEPHrine (EENT)
Administration
Apply topically to the skin and mucous membranes of the eye, nose, mouth, throat, or larynx.
For ophthalmic use, parenteral preparations may be injected intracamerally or subconjunctivally.
For local oral use, parenteral preparations may be infiltrated into buccal and mucosal vestibules.
Ophthalmic Administration
Ophthalmic solutions are intended for topical use only and must not be injected. For injection, only parenteral preparations should be used.
Usually apply topically to the conjunctiva of the affected eye(s).
To avoid visual disturbances resulting from mydriasis, administer at bedtime whenever possible.
Ophthalmic preparations generally should not be used in conjunction with the wearing of soft contact lenses, since epinephrine may cause adrenochrome staining (black discoloration) of the lenses.
When separate solutions of epinephrine and a topical miotic are used, the miotic should be instilled 2–10 minutes prior to epinephrine because of the limited capacity of the conjunctival sac.
May be injected intracamerally (into the anterior chamber of the eye) or subconjunctivally (beneath Tenon’s capsule) (e.g., to control hemorrhage or produce mydriasis).
To provide rapid mydriasis during surgery (e.g., cataract extraction), apply topically to the conjunctiva or inject into the anterior chamber of the eye.
To break posterior synechiae†, apply topically via a saturated cotton wick placed in the lower conjunctival cul-de-sac or inject subconjunctivally for synechiae unresponsive to topical therapy.
Nasal Administration
Nasal solutions are intended for topical use only and must not be injected.
Apply topically to nasal mucosa as drops or spray or with a sterile swab.
Dosage
Available as epinephrine hydrochloride; dosage expressed in terms of epinephrine.
When epinephrine is used as a mydriatic, it is less effective in dark than in light colored eyes; higher concentrations and/or dosages may be needed in patients with brown or hazel eyes.
Ocular discomfort and conjunctival irritation associated with topical instillation in the eye may be decreased by switching to a lower concentration.
Pediatric Patients
Nasal Congestion Intranasal LocalChildren ≥6 years of age: To produce nasal decongestion, apply a 0.1% (1:1000) solution topically as drops or spray to mucosa as required. Solution concentrations of 1:10,000 to 1:2000 also have been used.
Adults
Open-Angle Glaucoma Ophthalmic TopicalUsual dosage is 1 or 2 drops of a 1 or 2% ophthalmic solution once or twice daily instilled in the affected eye(s); however, dosing frequency may vary from once every 2–4 days to 4 times daily.
Adjust concentration and dosage to individual requirements and responses as determined by tonometric readings before and during therapy.
Mydriasis for Surgery Ophthalmic TopicalApply 1 or more drops of a 0.1% (1:1000) solution topically to the conjunctiva 1–3 times or as necessary to control bleeding or to provide a mydriatic effect during surgery†.
Ophthalmic Local InjectionIntraocular injections of 1:10,000 (0.01%) to 1:1000 (0.1%) concentrations can be used to provide mydriasis during surgery; this also can control bleeding.
In round-pupil cataract extraction, 0.2 mL (0.2 mg) of a 1:1000 injection may be injected intracamerally; in other cases of cataract extraction, 0.1 mL (0.1 mg) of a 1:1000 injection may be injected subconjunctivally.
Mydriasis for Synechiae Ophthalmic TopicalTo break posterior synechiae†, a cotton wick saturated with epinephrine is placed in the lower conjunctival cul-de-sac.
Ophthalmic Local InjectionTo break posterior synechiae† unresponsive to topical therapy, 0.1 mL of a solution containing equal parts of 0.1% (1:1000) epinephrine, 4% cocaine, and 1% atropine may be injected at the limbus.
Mydriasis for Ophthalmoscopy Ophthalmic TopicalTo provide mydriasis for ophthalmoscopy† in patients predisposed to angle closure, a carbonic anhydrase inhibitor (e.g., 250 mg of acetazolamide) and glycerin 1–1.5 g/kg are given orally 2 hours and 1 hour, respectively, prior to epinephrine. After the eye is anesthetized topically with a drug other than cocaine, the tip of a 1 × 5 mm strip of filter paper moistened with 1 or 2% epinephrine ophthalmic solution is inserted in the inferior cul-de-sac for 1–3 minutes.
Superficial Bleeding EENT TopicalAs a topical hemostatic agent, solution concentrations of 1:50,000 (0.002%) to 1:1000 (0.1%) may be sprayed or applied with cotton or gauze to the skin or mucous membranes of the eye, nose, mouth, throat, or larynx.
To control mucosal bleeding, a 0.1% (1:1000) solution can be applied topically as drops or spray to mucosa as required.
To control bleeding during ocular surgery, apply 1 or more drops of a 0.1% (1:1000) solution topically to the conjunctiva 1–3 times or as necessary.
EENT Local InjectionInjections of 1:10,000 (0.01%) to 1:1000 (0.1%) concentrations can be used to control bleeding (e.g., during surgery). To control ocular bleeding, inject these concentrations into the anterior chamber of the eye or subconjunctivally.
For use as a local hemostatic agent in combination with local anesthetics (e.g., during ocular surgery), epinephrine may be used in concentrations of 1:200,000 to 1:50,000; 1:200.000 is used most commonly.
To control bleeding during oral surgery†, infiltrate the buccal and labial vestibules of the maxilla and mandible in each quadrant with 4 mL of a 0.0005% (1:200,000) solution.
Adjunct to Local Anesthesia EENT Local InjectionTo localize and prolong the duration of local anesthesia, epinephrine may be used in concentrations of 1:500,000 to 1:50,000; 1:200.000 is used most commonly.
Adjunct to Other Local Drugs Ophthalmic Local InjectionTo enhance intraocular penetration and prolong the duration of subconjuntivally injected drugs†, epinephrine may be used in concentrations of 1:200,000 to 1:50,000; 1:200.000 is used most commonly.
Ophthalmic TopicalTo aid in botulinum toxin therapy for strabismus†, instill 1 drop of an epinephrine ophthalmic solution in the affected eye as a local vasoconstrictor.
Conjunctivitis Ophthalmic LocalFor conjunctrival decongestion, apply 1 or more drops of a 0.1% (1:1000) solution topically to the conjunctiva 1–3 times or as necessary.
Nasal Congestion Intranasal LocalTo produce nasal decongestion, apply a 0.1% (1:1000) solution topically as drops or spray to mucosa as required. Solution concentrations of 1:10,000 to 1:2000 also have been used.
Special Populations
Geriatric Patients
No specific dosage recommendations, but repeated tonometric readings during glaucoma therapy are especially advisable in this age group.
Warnings
Contraindications
Warnings/Precautions
Warnings
Narrow AngleCaution in patients with a narrow angle since pupil dilation may precipitate an acute attack of angle-closure glaucoma.
AphakiaChronic therapy may produce reversible macular edema in aphakic patients; caution is advised.
Changes in central vision in aphakic patients should prompt evaluation for maculopathy; epinephrine discontinuance usually is followed by improvement in visual acuity and ophthalmoscopic findings within 1 month but may not be maximal for 6 months or longer.
Cardiovascular EffectsConsider cardiovascular status before initiating therapy.
Use with caution in patients with vascular hypertension or cardiac disorders, including arrhythmias and cardiovascular disease (e.g., coronary artery disease).
Use with extreme caution in patients with degenerative heart disease. (See Asthma and Emphysema under Cautions.)
Use with caution, if at all, prior to or during surgery with cyclopropane or halogenated hydrocarbon anesthetics such as halothane. The danger of ventricular arrhythmias such as VPCs, tachycardia, or fibrillation may be increased.
If epinephrine is used prior to ocular surgery, especially for injection with a local anesthetic, systemic sympathomimetic effects may occur; surgery should not be started until restlessness has subsided.
Overdosage or inadvertent IV administration may cause cerebrovascular hemorrhage secondary to a marked increase in blood pressure.
Asthma and EmphysemaUse with extreme caution in patients with long-standing bronchial asthma or emphysema who have developed degenerative heart disease.
Diabetes, Hyperthyridism, and Cerebral ArteriosclerosisUse with caution in diabetic and hyperthyroid patients and those with cerebral arteriosclerosis.
Sensitivity Reactions
Allergic ReactionsOphthalmic use may cause allergic reactions (sensitization reaction to chronic therapy) characterized by diffuse vascular engorgement, follicular hypertrophy, chemosis, conjunctivitis, and/or iritis. Allergic contact dermatitis of the eyelids, producing such symptoms as edema of the lower lids, thick yellow discharge, and crusting and fissuring of the skin of the eyelids, also may occur.
Allergic reactions occasionally may be caused by the preservatives in the preparations.
Some ophthalmic formulations contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.
General Precautions
Ocular IrritationAdverse local reactions occur frequently during topical ocular therapy and prolonged use may not be tolerated.
Topical application to the conjunctiva frequently causes ocular discomfort and conjunctival irritation including transient burning or stinging, lacrimation, pain or ache around or in the eye, and rebound conjunctival hyperemia.
Some of these local ocular effects may be reduced if a lower epinephrine concentration is used.
Ocular Pigmentary ChangesProlonged use may result in localized melanin-like pigmentary (e.g., adrenochrome) deposits in the conjunctiva, eyelids, and/or roughened or edematous areas of the cornea. Such pigmenation may be increased by use of old or disclored solutions containing oxidixed epinephrine.
Large brownish-black casts occasionally may form in the lacrimal sac and nasolacrimal duct, resulting in obstruction and epiphora. These casts may be removed by irrigation.
Increased IOPRarely, a temporary but clinically important increase in IOP and impairment of outflow facility (even when the angle of the eye remained open) have occurred in glaucoma patients when epinephrine was used initially without a miotic.
Acute Angle ClosureIn patients with angle-closure glaucoma, dilation of the pupil may precipitate an acute attack.
Mydriasis, Blurred Vision, and Light SensitivityMydriasis, blurred vision, and sensitivity to light may occur in glaucoma patients; inconvenience may be minimized if epinephrine is administered at bedtime or following a miotic.
Corneal EffectsProlonged ophthalmic use may cause corneal edema; after very prolonged use, superficial blood vessels in the eye may lose the ability to constrict.
Intracameral injection of epinephrine 1:1000 has been associated with endothelial damage, irreversible edema, and opacification of the cornea.
Other Local EffectsHeadache or browache frequently occurs at the beginning of ocular therapy and may diminish with continued treatment.
Systemic EffectsOphthalmic use occasionally causes systemic sympathomimetic effects such as palpitation, tachycardia, extrasystoles, ventricular premature complexes, hypertension, occipital headaches, pallor, trembling, faintness, and increased perspiration. Such effects are common with local ophthalmic injection.
Excessively large local dosages may cause cerebral hemorrhage and ventricular fibrillation. Patients with preexisting hypertension, hyperthyroidism, coronary artery disease, or advancedcerebral arteriosclerosis are particulaly susceptible.
Systemic sympathomimetic effects occur very rarely after application to the conjunctiva but are more likely to occur if the drug is instilled after the corneal epithelium has been damaged or permeability is increased by tonometry, surgery, inflammation, or topical application of a local anesthetic.
Systemic sympathomimetic effects also may occur with other mucosal (e.g., intranasal) use.
Use of Fixed CombinationWhen used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.
Specific Populations
PregnancyCategory C.
LactationRisk unknown.
Pediatric UseSafety and efficacy of ophthalmic solutions not established.
Nasal solutions should be used in children <6 years of age only under the advice af a clinician.
Geriatric UseUse with caution. Melanin-like pigmentary deposits may occur within translucent conjunctival cysts.
Common Adverse Effects
Ocular use: irritation and discomfort, ocular pain or ache, browache, headache, conjunctival hyperemia, allergic lid reactions.
Intranasal use: CNS symptoms (e.g., nervousness, restlessness) rebound nasal congestion. Slight stinging after intranasal application (because of the presence of sodium bisulfite).
What other drugs will affect EPINEPHrine (EENT)
Specific Drugs
Drug
Interaction
Comments
Anesthetics, general (e.g., halogenated hydrocarbons [e.g., halothane], cyclopropane)
Increased cardiosensitivity to epinephrine
Use with caution, if at all; increased risk of ventricular arrhythmias such as ventricular premature complexes, tachycardia, or fibrillation; contraindicated with chloroform, trichloroethylene, or cyclopropane
May not be absorbed rapidly enough with topical hemostatic use to present a problem in short procedures
Propylactic lidocaine or procainamide may provide some protection
IV propranolol may reverse arrhythmias
Antidepressants, tricyclic
Potentiation of epinephrine effects (especially on heart rate and rhythm)
Antihistamines, first generation (especially diphenhydramine, Chlorpheniramine" href="/drugs/dexchlorpheniramine-4069/">Dexchlorpheniramine, tripelennamine)
Potentiation of epinephrine effects (especially on heart rate and rhythm)
β-Adrenergic blocking agents
Less than additive IOP reduction
Therapeutically beneficial
Carbonic anhydrase inhibitors
Additive IOP reduction
Therapeutically beneficial
Digoxin
Increased cardiosensitivity to epinephrine
Avoid epinephrine with high digoxin dosages
Miotics (topical)
Additive IOP reduction; eipnephrine decreases miosis and ciliary spasm; miotics decrease mydriasis and blurred vision
Therapeutically beneficial
Osmotic agents (topical)
Additive IOP reduction
Therapeutically beneficial
Thyroid agents
Potentiation of epinephrine effects (especially on heart rate and rhythm)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions